Publisher Correction: CRISPR target prediction remains blunt tool for clinical applications.
In the version of this article initially published, we reported that Sangamo's SB-318 had failed to change baseline leukocyte α-L-iduronidase in a phase 1/2 trial. The drug failed to change baseline plasma α-L-iduronidase but did increase leukocyte α-L-iduronidase to within the normal range. The error has been corrected in the HTML and PDF versions of the article.